FDA approves Genzyme pediatric leukemia drug

12/30/2004 | Wall Street Journal, The

The FDA approved Genzyme's leukemia drug, Clolar, assigning orphan status to the drug developed for treating patients age 21 and younger who do not respond to chemotherapy. Genzyme expects the drug to be available in January, at an estimated price of $34,000 per dose. One expert said it is likely the drug also will be used off-label in combination with other treatments for adult patients.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC